CA2415354C - Phospholipid derivatives of valproic acid and mixtures thereof - Google Patents

Phospholipid derivatives of valproic acid and mixtures thereof Download PDF

Info

Publication number
CA2415354C
CA2415354C CA002415354A CA2415354A CA2415354C CA 2415354 C CA2415354 C CA 2415354C CA 002415354 A CA002415354 A CA 002415354A CA 2415354 A CA2415354 A CA 2415354A CA 2415354 C CA2415354 C CA 2415354C
Authority
CA
Canada
Prior art keywords
vpa
pharmaceutical composition
valproic acid
pharmaceutically acceptable
phospholipid moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002415354A
Other languages
English (en)
French (fr)
Other versions
CA2415354A1 (en
Inventor
Alexander Kozak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D Pharm Ltd
Original Assignee
D Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Pharm Ltd filed Critical D Pharm Ltd
Publication of CA2415354A1 publication Critical patent/CA2415354A1/en
Application granted granted Critical
Publication of CA2415354C publication Critical patent/CA2415354C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002415354A 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof Expired - Fee Related CA2415354C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
US09/614,271 2000-07-12
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (2)

Publication Number Publication Date
CA2415354A1 CA2415354A1 (en) 2002-01-31
CA2415354C true CA2415354C (en) 2009-09-29

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002415354A Expired - Fee Related CA2415354C (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Country Status (20)

Country Link
US (2) US6313106B1 (https=)
EP (1) EP1315506B1 (https=)
JP (1) JP5140224B2 (https=)
KR (1) KR100801213B1 (https=)
CN (1) CN100536851C (https=)
AT (1) ATE461697T1 (https=)
AU (2) AU7096201A (https=)
BR (1) BR0112337A (https=)
CA (1) CA2415354C (https=)
CY (1) CY1110113T1 (https=)
CZ (1) CZ305745B6 (https=)
DE (1) DE60141636D1 (https=)
DK (1) DK1315506T3 (https=)
ES (1) ES2343403T3 (https=)
HU (1) HU229320B1 (https=)
IL (1) IL153147A0 (https=)
MX (1) MXPA03000326A (https=)
NZ (1) NZ522788A (https=)
PT (1) PT1315506E (https=)
WO (1) WO2002007669A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
CN1649600A (zh) 2002-02-28 2005-08-03 A&D生物科学公司 氟西汀及类似物的糖醛酰胺、苷和原酸酯苷及其应用
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
CA2484891A1 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
JP2015533114A (ja) * 2012-05-08 2015-11-19 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物及び方法
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
CA2049028A1 (en) 1989-03-07 1990-09-08 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (https=) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
DE60141636D1 (de) 2010-05-06
IL153147A0 (en) 2003-06-24
CA2415354A1 (en) 2002-01-31
PT1315506E (pt) 2010-05-17
AU2001270962B2 (en) 2006-03-16
DK1315506T3 (da) 2010-05-31
HUP0302635A2 (hu) 2003-11-28
BR0112337A (pt) 2004-06-08
US6313106B1 (en) 2001-11-06
JP2004509854A (ja) 2004-04-02
JP5140224B2 (ja) 2013-02-06
EP1315506A2 (en) 2003-06-04
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
CN1774252A (zh) 2006-05-17
KR20030034099A (ko) 2003-05-01
AU2001270962B8 (en) 2006-08-10
HUP0302635A3 (en) 2007-06-28
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
NZ522788A (en) 2005-04-29
MXPA03000326A (es) 2004-12-13
WO2002007669A2 (en) 2002-01-31
EP1315506B1 (en) 2010-03-24
ES2343403T3 (es) 2010-07-30
CN100536851C (zh) 2009-09-09
CZ305745B6 (cs) 2016-03-02
US20040033987A1 (en) 2004-02-19
CZ200386A3 (cs) 2003-06-18
EP1315506A4 (en) 2005-03-30
CY1110113T1 (el) 2015-01-14
HU229320B1 (en) 2013-10-28

Similar Documents

Publication Publication Date Title
CA2415354C (en) Phospholipid derivatives of valproic acid and mixtures thereof
AU2001270962A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
US6153653A (en) Choline compositions and uses thereof
US6682758B1 (en) Water-insoluble drug delivery system
Zhao et al. Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with “lock-in” function
JP7610208B2 (ja) 足場部分から調製した脂質結合体
US6251946B1 (en) Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
EP3388417A1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
SK285135B6 (sk) Derivát 1,3-propándiolu a jeho použitie
EP1140017B1 (en) Water-insoluble drug delivery system
CA3055464A1 (en) Acefapc for the treatment of acetylcholine-dependent diseases
CA2667150A1 (en) Omega-3 lipid compounds
Kurz et al. Drug–phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A2
KR20220140563A (ko) 카나비노이드 설페이트 에스테르, 이들의 염 및 이의 사용
US7173018B2 (en) Phospholipid derivatives of non-steroidal anti-inflammatory drugs
JP2019529517A (ja) ニトロソ化およびアルキル化反応を媒介するニトロアルケンの新規可逆的窒素酸化物誘導体
IL153147A (en) Pharmaceutical compositions comprising phospholipid conjugates of valproic acid or derivatives thereof
KR100263085B1 (ko) 신규의 알카로이드 유도체, 이의 용도 및 이를 함유한 제약적 조성물
JP2025505177A (ja) リボースリンカーおよびその複合体
DE102015201148B4 (de) Verwendung von Phenylphosphaten und deren Prodrugs als Arzneimittel in der Krebstherapie
Reddy et al. Lipid-based anticancer prodrugs
EP4216960A1 (en) Compound for use in the treatment of protozoal diseases and process for production of said compound

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170710